ImmunityBio, Inc. (IBRX) vs Kymera Therapeutics, Inc. (KYMR)

ImmunityBio, Inc. and Kymera Therapeutics, Inc. are both Biotechnology companies. ImmunityBio, Inc. and Kymera Therapeutics, Inc. are of similar size ($9.7B and $9.2B). ImmunityBio, Inc. grew revenue faster over the last twelve months: 192.9% against 134.8%. Kymera Therapeutics, Inc. has the higher net margin (−285.3% vs −598.6%) and the lower return on invested capital (−26.7% vs 0.00%). Across the 17 metrics below, ImmunityBio, Inc. leads on 11 and Kymera Therapeutics, Inc. on 6.

Valuation

Metric IBRX KYMR Biotechnology median
P/E n/m n/m 7.88
P/S 53.46 105.17 11.47
P/B n/m 7.32 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 56.01 98.60 10.73
Earnings yield (11.49%) (2.88%) (28.84%)
Free cash flow yield (3.25%) (2.15%) (23.03%)

Profitability

Metric IBRX KYMR Biotechnology median
Gross margin 99.34% 100.00% 65.16%
Operating margin (151.88%) (333.50%) 0.00%
Net margin (598.56%) (285.33%) 0.00%
Free cash flow margin (173.76%) (226.62%) 0.00%
Return on equity 122.85% (24.15%) (57.72%)
Return on assets (192.58%) (21.58%) (49.22%)
Return on invested capital 0.00% (26.72%) 0.00%

Growth

Metric IBRX KYMR Biotechnology median
Revenue growth (TTM) 192.92% 134.84% 5.64%
EPS growth (last fiscal year) 38.71% (23.83%) —
Revenue growth, 5-year CAGR 184.76% 2.87% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IBRX KYMR Biotechnology median
Debt to equity (0.74) 0.00 0.00
Current ratio 5.72 10.34 4.73
Net debt to EBITDA (0.97) 2.42 0.96

Dividend

Metric IBRX KYMR Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric IBRX KYMR Biotechnology median
Market cap 9.19b 9.69b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack